Tenderwize
Retour à la recherche

Open-house rebate contracts for valproic acid (non-retarded form)

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 03, 2028 · 583 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Valproinsäure in nicht retardierter Darreichungsform, ATC N03AG01

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

Paper documents sent to the wrong channel or not received as original duplicate copies by the stated deadline may be in...

Only pharmaceutical companies are eligible, and a signed declaration of reliability is mandatory.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Open-house rebate agreements for the medicinal product valproic acid in non-retarded dosage form, ATC N03AG01.
  • Supply contract for pharmaceutical products.
Afficher le résumé complet

This is an open-house pharmaceutical supply arrangement by AOK Bayern for valproic acid in non-retarded form (ATC N03AG01), not a competitive award procedure in the usual sense. The buyer intends to conclude identical, non-exclusive contracts with all interested pharmaceutical companies that meet the stated suitability requirement. The contract period runs from 2026-06-01 to 2028-05-31, with contract conclusion possible until 2028-04-03. Submission is possible electronically via DTVP with a qualified electronic signature or in paper form in duplicate originals; German language is required, and non-German documents must be submitted with German translation. No contract value is provided.

Risques

Paper documents sent to the wrong channel or not received as original duplicate copies by the stated deadline may be in...

Only pharmaceutical companies are eligible, and a signed declaration of reliability is mandatory.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability must be submitted.
  • The signed contract and the completed annex 'Determination of the medicinal products covered by the contract' must be submitted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate contracts for valproic acid (non-retarded form)

Single lot from structured data. Scope: open-house rebate agreements for pharmaceutical products containing valproic acid in non-retarded dosage form, ATC N03AG01. The arrangement is non-exclusive and identical for all qualifying pharmaceutical companies. Place of performance is Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

May 2026 - May 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Apr 03, 2028

Détails de la procédure

Date de publication
14 Apr 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
255761-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30